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Autism is a devastating childhood condition that has emerged as an increasing social concern just as it has
increased in prevalence in recent decades. Autism and the broader category of autism spectrum disorders are
among the increasingly seen examples in which there is a fetal basis for later disease or disorder.
Environmental, genetic, and epigenetic factors all play a role in determining the risk of autism and some
of these effects appear to be transgenerational. Identification of the most critical windows of developmental
vulnerability is paramount to understanding when and under what circumstances a child is at elevated risk for
autism. No single environmental factor explains the increased prevalence of autism. While a handful of
environmental risk factors have been suggested based on data from human studies and animal research, it is
clear that many more, and perhaps the most significant risk factors, remain to be identified. The most
promising risk factors identified to date fall within the categories of drugs, environmental chemicals,
infectious agents, dietary factors, and other physical/psychological stressors. However, the rate at which
environmental risk factors for autism have been identified via research and safety testing has not kept pace
with the emerging health threat posed by this condition. For the way forward, it seems clear that additional
focused research is needed. But more importantly, successful risk reduction strategies for autism will require
more extensive and relevant developmental safety testing of drugs and chemicals.
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F
or the purpose of this review, autism, autism
disorder, and autism spectrum disorder (ASD)
will be referred to simply as autism. Autism has
three primary features that underscore its relationship
with environmental risk factors. First, the prevalence of
autism has increased in recent decades at an alarming rate.
Second, as with most neurodevelopmental (or immunolo-
gical) disorders, autism is chronic in nature and the
ramifications of the dysfunction are borne across a
lifetime. Finally, autism is but one of a disturbingly large
cadre of chronic conditions (e.g. asthma, type 1 diabetes,
metabolic syndrome, schizophrenia, sleep disorders) that
have followed similar paths of increased prevalence. These
conditions all have early life origins (1), appear to be
connected to grids or patterns of additional comorbidities,
(2, 3) and have environmental risk factors that, at least in
part, are yet to be identified. An effective environmental
risk reduction strategy for one of these diseases or
conditions is likely to have a broader relevance that could
encompass other developmentally based diseases.
Research into the etiology of autism has intensified to
meet the goals of: (1) providing fundamental information
concerning the nature of autism needed for improving
quality of life strategies, and (2) aiding the identification
of causative risk factors that are targets for public health
risk reduction efforts. We agree with other recent reviews
on this subject (4) that additional targeted research is
needed to support these goals. But increased research
usually follows epidemics like autism, childhood asthma,
and metabolic syndrome rather than preceding and
preventing them. Instead, developmental toxicity safety
testing of drugs and chemicals (e.g. neurological and
immunological) is the frontline process used to identify
environmental risk factors, reduce risks to children and
pregnant women, and prevent these epidemics. Based on
the outcomes of safety testing relative to autism, asthma,
and metabolic syndrome, this public health protection
strategy has been inadequate at best. As will be discussed
in the following sections, no single environmental factor
is sufficient to explain the current autism epidemic (5)
and more risk factors are likely to be identified in coming
years. The different categories of factors that determine
the overall risk of autism and the roles played by
environmental risk factors are illustrated in Fig. 1.
(page number not for citation purpose)
REVIEW ARTICLE
Emerging Health Threats Journal 2011. # 2011 Rodney R. Dietert et al. This is an Open Access article distributed under the terms of the Creative Commons
Attribution-Noncommercial 3.0 Unported License (http://creativecommons.org/licenses/by-nc/3.0/), permitting all non-commercial use, distribution, and reproduction
in any medium, provided the original work is properly cited.
1
Citation: Emerging Health Threats Journal 2011, 4: 7111 - DOI: 10.3402/ehtj.v4i0.7111
The landscape of autism
Description
Autism is a moderately to highly heritable condition (6, 7)
that favors the male gender (8). It is considered to be a
Pervasive Developmental Disorder, which means that
developmental milestones are not met in a timely manner
over a broad spectrum of assessment points. In general,
individuals with autism are markedly to severely impaired
for the necessary components that would allow for
appropriate social interaction. These include impaired
non-verbal language skills in which they do not look at
the eyes of others, cannot read body language, do not
have the sense of others as being separate from them-
selves, and do not have the internal neural mirror
capacity for empathy to the point of having no concept
of the needs of others or knowing when another is in
distress. They often lack verbal language skills as well (9).
Along with communication and social skills impairments,
individuals with autism often have extremely narrow
interests, preferring to focus on one or two interests
obsessively. They often rely on repetitive motor manner-
isms (e.g. hand flapping, spinning in circles, etc.) as a
means of self-calming or self-stimulation (9).
Diagonosis
A diagnosis of autism is only considered after two other
disorders have been ruled out: Rett’s Disorder, which
includes severe mental retardation and Childhood Disin-
tegrative Disorder, in which the child regresses after 2
years of normal development not just in language and
social skills but often also in the areas of bladder and
bowel control. The delays or abnormal functioning must
be present in the child before they reach 3 years of age (9).
For diagnosis, children must exhibit at least two impair-
ments of social interaction. For diagnosis, children must
exhibit a total of six or more symptoms from among
three discrete sets. At last two symptoms of social
impairment, at least one language-based symptom and
at least two symptoms showing repetitive, stereotypical
patterns related to behavior, interest, and activities must
be evident as well (9).
Prevalence
Autism was originally identified in 1943 (10) and was
more formally recognized by the American Psychiatric
Association in 1980 (11). Several decades ago, a diagnosis
was made for every 1 in 1,000 children, but over the last
decade the prevalence rate for the diagnosis of autism has
exploded. Now approximately 1 in 110 children or 1% of
children in the United States are diagnosed with autism
(12). A portion of the increased prevalence is attributable
to better awareness by physicians and parents, changed
criteria for diagnosis, and improved diagnostic tools.
However, a recent study of autism in California estimated
that these diagnostic variables across the decades could
only account for a quarter of the recent increase in
prevalence (13). The remainder of this alarming trend
must come from early life environmental or physical
conditions or environment-gene interactions that impact
the development of children both in utero and in early
childhood. The epidemic nature of these changes is most
easily quantified by the flow of autistic individuals
through the school systems. Between 1991 and early
2001, the rate of children in US schools with autism
increased by 1,700% (14). Ironically, while the increased
prevalence appears to be an actual epidemic, a recent
study of the current autism records-based surveillance
system concluded that recent estimates of the prevalence
of autism are likely to be conservative (15).
Parallel epidemics and our safety testing standards
Autism is one of several childhood illness epidemics (e.g.
childhood asthma, metabolic syndrome) that have
emerged together in recent decades. This co-emergence
of childhood epidemic patterns may provide a clue to
those changes in environmental exposures that are of
greatest concern for pregnant women and children. Other
Fig. 1. The pie chart illustrates the most likely risk factors for autism. At issue is the way in which these factors act either independently
and/or though various interactions to produce autism. To date, much of this remains to be determined.
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researchers have noted this parallel and commented on
these possible associations for autism with asthma (16,
17) and metabolic syndrome (18). These conditions affect
an alarming percentage of children, particularly in
countries like the United States and United Kingdom.
The existence of multiple major childhood epidemic
patterns should be sufficient cause for us to abandon
outdated and largely ineffective safety testing approaches
that have produced these results over the past 30 years. As
discussed later, more effective approaches for protecting
the health of children are needed if not significantly
overdue (19).
Socioeconomic impact
Each new pediatric diagnosis of autism carries with it
specific implications for family, community, and national
socioeconomic systems. These extend from the child or
autistic adult to the immediate family but then rapidly
encompass the health care financing system, physicians’
perceptions, educational systems, the need for long-term
half-way houses, adult employment for the disabled, and
the economic trajectory for the autistic individual and
immediate family members. Knapp et al. (20) used a
combination of autism prevalence information, services
provided, and lost productivity in the UK to estimate
that the cost of supporting children with autism was 2.7
billion pounds per annum, while the cost for adults was
25 billion pounds per annum.
Children with autism and their families have a
significantly reduced quality of life that affects many
different domains (e.g. economic, social, educational,
psychological) (21). Parents of children with autism
were seven times more likely than parents of typically
developing children to state that child care problems had
affected their employment (22). One US study found that
direct impact on family annual income was a loss of
approximately 14% (23). Not surprisingly, raising an
autistic child presents additional stress and psychological
challenges for the parents (24). Children with autism
often have a greater prevalence of sleep problems than
typically developing children (2527). A recent study
suggested that parents of autistic children themselves also
have a greater prevalence of sleep problems than did
parents of typically developing children (28).
Remarkably, Ja¨rbrink (29) estimated that in Sweden,
the societal cost was approximately 50,000 euros per
annum per child and that parents of autistic children
devoted an extra 1,000 hours of time (in support of their
children’s needs) compared with parents of typically
developing children. In a US study of the vocational
rehabilitation system, Cimera and Cowan (30) reported
that adults with autism supported by these services
increased by more than 121% from 2002 to 2006.
Additionally, this group of adults was among the most
costly within the system.
The levels of medical care costs are unlikely to improve
significantly in the near future. Training of broader
segments of the medical care community for the specia-
lized considerations of autistic patients has lagged behind
the epidemic itself. For example, a recent survey of
primary care physicians found that a greater proportion
of this front-line group of health care providers lacked
self-confidence in their ability to care for autistic children
(31).
Gene-environment interactions including
epigenetic considerations
Studies examining gene-environment interactions are
underway and are encouraging as they involve the
prospective collection of samples and genetic information
among a large unselected birth cohort. These types of
human studies have the potential to narrow the landscape
of likely environmental risk factors (32). One of the
concerns in precisely identifying the relationship between
the beginning of the autism epidemic and a modified
environment is the potential environmental epigenomic
influences. Environmentally mediated changes in fetal
programming can be limited to an individual’s prenatal
period of development or alternatively, may have multi-
generational effects where alteration in control of gene
expression may appear in later generations after the
introduction of an environmental risk factor. Such multi-
generational effects have been reported between tobacco
smoking and childhood asthma (33). However, it is
apparent that epigenetic effects also extend to autism
(34, 35).
Critical developmental windows for
environmental risk of autism
Autism is a developmental disorder meaning that altera-
tion or disruption of specific maturational steps in the
brain is thought to be prerequisite for developing the
condition. But precisely when does this disruption occur?
Clearly, with autism now routinely diagnosed before
2 years of age, sensitive windows of developmental
vulnerability must occur during the prenatal and/or early
postnatal periods of development. Within that overall
period of development, there are likely to be narrower
windows of greater risk for environmental exposures
and conditions. Some possible critical windows were
discussed in a prior review of autism (36).
It seems clear that the prenatal period should be a
primary focus for risk of autism (37, 38). Early mid-
gestational exposure of rats to valproic acid (VPA)
produced autism-like characteristics in the offspring
(39). The association of preterm birth with autism
suggests that prenatal windows were particularly impor-
tant in risk of autism (40). Using meta-analysis, Gardener
et al. (5) concluded that pregnancy complications (based
on maternal prenatal medication) were associated with an
Environment and autism
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increased risk of autism; however, no single prenatal
factor was identified. These findings are also supported
by other striking examples where the fetal environment
significantly impacts later-life neurological status (41).
The information from these studies supports the existence
of important prenatal windows. However, it does not
exclude the potential for significant postnatal exposure
effects in risk of autism.
Figure 2 illustrates the potential windows of develop-
mental vulnerability that have been described to date. At
present and based on the best examples of known human
risk factors, the first trimester of pregnancy is one
probable critical window for some categories of environ-
mental agents (4245). But some studies suggest there are
likely to be other critical windows that exist later in
pregnancy and/or in the newborn (46).
Routes to autism
Autism exhibits phenotypic heterogeneity, which suggests
that a mechanistic route does not encompass a single
pathway but includes disturbances to myriad pathways or
processes that culminate in an autism diagnosis (Fig. 1).
Although multiple factors contribute to autism etiology,
including genes and environmental agents, potential
mechanisms appear common to autistic patients and
indicate that a mechanistic route to autism is a gene-
environment interaction. Therefore, the challenge
in describing autism etiology requires identifying candi-
date genes and likely environmental factors and the
downstream effects that arise from environmentally
induced disturbances to genes and gene products. While
several different mechanisms of developmental disruption
have been suggested to contribute to autism, a detailed
discussion of these is beyond the scope of the present
review. Briefly, Herbert et al. (47) identified candidate
genes for autism that are influenced by environmental
factors but that have been overlooked because they do not
have an explicit linkage to the central nervous system;
therefore, candidate genes may be numerous. Although
the brain may be altered by environmental factors directly,
autism may also result from downstream effects of
environmentally modulated changes to other systems
(47). Herbert (48) also reported that mechanistic routes
to autism occur via developmental disturbances to three
main pathways/processes: neurotransmission pathways,
redox and methylation pathways, and increases in de novo
copy number variants. Effects on other systems, such as
the immune and endocrine systems, also, may be indirect
downstream effects that lead to changes in neurological
development. Current evidence indicates that a propor-
tion of autism cases result from the interaction of multiple
susceptible genetic loci (49) and that environmental
interactions with susceptible genetic loci produce myriad
routes that may culminate in an autistic phenotype.
Environmental risk factors
In the search for the environmental risk factors of autism,
the data are derived from both human and animal
Conception 1st Trimester 2nd Trimester 3rd Trimester Birth
Viral Infection–Hospitalization
Bacterial Infection–Hospitalization
Murine Viral Infection
Absence of Food Aversion and Vomiting
Generalized Maternal Stressors
Misoprostal
Thalidomide
Valproicacid
Terbutaline
Vitamin D Deficiency
Critical Prenatal Windows for Risk of Autism
Fig. 2. Putative critical windows of developmental vulnerability for autism are shown based on reports involving potential
environmental risk factors. Information is included from human studies as well as from animal data. References for each risk factor
and window are as follows: Viral Infection*Hospitalization (92), Absence of Food Aversion and Vomiting (44), Misoprostal (70),
Thalidomide (109), Valproic Acid (37), Bacterial Infection*Hospitalization (92), Murine Viral Infection (110), Generalized Maternal
Stressors (102), Terbutaline (111), and Vitamin D Deficiency (77).
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studies. Direct human exposures usually involve drugs,
environmental chemicals, medical procedures, dietary
factors or stress involving the mother (and sometimes
the father) shortly before conception, the pregnant
woman, the nursing mother, and/or the young child. A
majority of epidemiology studies are examining the
associations between exposures and/or body burden
estimates and autistic outcomes, and several large
scale studies are ongoing at present. In some cases
these human studies are buttressed by animal studies
where biological plausibility of the link between environ-
mental exposure and altered neurological development is
established. The precision of the representation of some
animal models of autism for the human condition has
been open to considerable discussion. But most research-
ers agree that environmental factors contributing to
human autism are likely to produce some detectable
developmental brain alterations in relevant animal
models. This has been an important concept in focusing
the search for the most important risk factors of autism.
Environmental chemicals
Myriad environmental chemicals have been implicated as
contributory factors to autism development. In a scien-
tific consensus statement by the Collaborative on Health
and the Environment’s Learning and Developmental
Disabilities Initiative (50), several environmental agents
were identified as strong contributors to learning and
developmental disabilities in humans. These included
arsenic, lead, manganese, mercury, pesticides, polybro-
minated diphenyl ethers (PBDEs), polychlorinated
biphenyls (PCBs), polycyclic aromatic hydrocarbons
(PAHs), and solvents. However, as previously mentioned
in the ‘routes to autism’ section, a direct effect on the
developing nervous system is not the only route to
autism. Environmental agents that affect other systems
during development may lead to downstream effects on
the developing brain. Limiting research to just those
agents that directly impact brain development may
exclude a multitude of triggers. In addition, no single
agent or specific combination of agents has been
identified as a trigger. It is more likely that certain
individuals with enhanced susceptibility to environmental
chemicals and with certain genetic predispositions are at
increased risk for autism after exposure to a variety of
environmental triggers including chemicals (51). It would
be nearly impossible to describe every single study
examining links between environmental chemicals and
autism. Therefore, this section will highlight chemicals
with the strongest associative evidence.
Heavy metals
Heavy metal contamination is ubiquitous and children
are generally more susceptible to heavy metal toxicity
than are adults, but heavy metal exposure received during
early development is difficult to discern after an autism
diagnosis. Regardless, several studies have evaluated
associations between autism and biomarkers of heavy
metal exposure and effects. The evidence that heavy metal
exposure leads to an autistic phenotype is increasingly
convincing. Sulfhydryl-reactive metals including arsenic,
cadmium, lead, and mercury are the metals most
commonly reported as being associated with autism
prevalence and risk. Kern et al. (52) evaluated hair
samples from autistic and control children and found
that levels of sulfhydryl-reactive metals were lower in
autistic children relative to control children, which
suggests that subgroups of autistic children may have
increased susceptibility to certain metals because they are
poor excretors or detoxifiers. Other metals may also
increase risk; Adams et al. (53) reported that severity of
autistic symptoms was influenced by body burdens of
aluminum, antimony, lead, and mercury as measured by
urinary excretion. Additional research into heavy metal
exposure and autism risk is warranted not only to
identify metals most commonly associated with increased
risk, but to determine the most appropriate biomarkers
for assessing risk.
Pesticides
A 2007 study of maternal exposures to agricultural
pesticides and autism incidence found that risk for autism
was consistently associated with exposure to organo-
chlorine pesticide applications during the period of
nervous system organogenesis (54). In a recent review,
Landrigan (4) indicated that a strong link existed between
exposure to chlorpyrifos, an organophosphate insecticide,
and autism. Several classes of pesticides act by dysregu-
lating the nervous systems of target species (i.e. organo-
chlorine, organophosphate, and carbamate insecticides),
and non-target species can be similarly affected by
environmental exposures. However, additional epidemio-
logical evidence is necessary to strengthen the link
between pesticide exposure and increased autism risk.
Other environmental chemicals
Strong evidence linking environmental neurotoxicants
and autism is scant; the majority of research papers
concerning these chemicals focus on neurotoxicological
endpoints in laboratory models. Regardless, neurotoxi-
cants are autism risk factors for two main reasons: (1)
many are known to disrupt neural development and (2)
environmental concentrations of several neurotoxicants
have increased over the past decades, somewhat tracking
with increases in autism prevalence. Messer (55) sug-
gested PBDEs as risk factors for autism not only because
during the period of time that autism prevalence has
increased, levels of brominated flame retardants have
increased immensely, but because PBDEs are analogs of
thyroid hormone. Binding of PBDEs to thyroid hormone
Environment and autism
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transporters and receptors during critical periods of
brain development may alter the course of development
toward an autistic phenotype (55). Similarly, PCBs are
developmental neurotoxicants that have been environ-
mental pollutants for decades. Certain PCB congeners,
notably those that disrupt thyroid hormone, may inhibit
or alter thyroid hormone-regulated gene expression and
push brain development toward an autistic phenotype
(56, 57). Other environmental pollutants, especially those
that disrupt endocrine and immune system signaling, may
also increase autism risk; however, data solidifying the link
between increased exposure and increased risk are limited.
Drugs
Exposure to pharmacological agents particularly during
pregnancy represents a highly relevant environmental
concern relative to the risk of autism. Some changing
trends in availability and use of certain categories of
prescription and over the counter drugs parallel the
changing prevalence of autism (17, 58). Additionally,
prenatal exposure to a handful of specific drugs such as
thalidomide and VPA are among the best examples to
date of known environmental risk factors. Finally, as will
be discussed later, the disconnection between the routine
drug safety screening usually performed and evaluation
of the risk of autism (e.g. via relevant developmental
neurotoxicity testing) means that the potential for some
categories of drugs to promote autism remains relatively
undetermined.
Valproic acid (VPA)
VPA is an antiepileptic drug and mood stabilizer in
addition to being a known human teratogen (59). When
the drug is taken during pregnancy, it can result in
children having a well-defined syndrome of abnormalities
affecting several systems known as the valproate syn-
drome (60). In children from women who have taken this
medication during pregnancy, autism spectrum disorders
are increased several fold (61). The dose and timing of
exposure may be key to the extent of the risk.
Results supporting human data have been seen in
animal models. In utero exposure of mice to VPA
produced autism-like signs in the offspring (62). The
VPA exposure produces developmental delays, deficits in
motor performance and social behavior, and alterations
in postnatal growth and development (6366). As in
humans, alterations of postsynaptic cell-adhesion mole-
cules appear associated with the condition (e.g. neuroligin
gene transcription) (62). The VPA is thought to alter gene
expression and increase oxidative stress (to which the
brain is very susceptible during critical windows of
development) (60).
Thalidomide
Thalidomide is a known human teratogen that, among
its actions, binds to cereblom and inhibits ubiquitin
ligase activity (67). Two studies have reported increased
incidences of autism in children following prenatal
exposure to thalidomide (68, 69). As discussed by Land-
rigan (4), the pattern of malformation noted has sug-
gested that the critical window of exposure is in the first
trimester.
Misoprostol
Misoprostol is a prostaglandin analog drug that is
prescribed for the prevention and treatment of gastric
ulcers. Because of its action on the uterus, it has also been
used for medical abortion. In a study in Brazil, Bandim
et al. (70) reported the association between misoprostol
during the first trimester of pregnancy and autism.
Beta 2 adrengeneric agonist drugs
Beta 2 adrenergic agonists such as terbutaline are used in
the treatment of asthma. At least one research group
reported that exposure in prenatal developmental is
associated with an elevated risk of autism spectrum
disorders as well as other neurophysiological outcomes
(71). While human reports describing this potential
association are limited, studies in animals provide
biological plausibility for this interaction (72).
Antipyretics
Fever suppression strategies and their possible implica-
tion for risk of autism has been an emerging topic of
consideration. Torres (58) suggested that antipyretic use
in early life should be examined as a possible link to the
risk of autism and other neurodevelopmental disorders.
These associations have not been firmly established but
are biologically plausible. Innate immune response differ-
ences in toll-like receptor responses have been reported
among autistic versus non-autistic children (73). Such
immune cell response differences would be key to
potential differences in fever responses. Additionally,
Becker and Schultz (17) pointed out that early life
acetaminophen use is a risk factor for asthma, and that
a similar concern may exist for some populations of
children relative to risk of autism. In a preliminary study
using parental surveys, Schultz et al. (74) found that
acetaminophen use, but not ibruprofen use, was asso-
ciated with an elevated risk of autistic disorder.
Dietary factors
Diet-influenced factors are part of the landscape of
potential environmental risk factors for autism that
have been largely overlooked until recently. Levels of
two diet-related factors that also can be affected
via pharmacological (supplements) or physical routes
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(sunlight) have taken on new importance in the search for
the environment-autism connection.
Vitamin D
Low prenatal levels of vitamin D have been suggested to
play a role in the risk of autism (75, 76). Some studies
have found that mothers of autistic children versus those
with non-autistic children have reduced serum vitamin D
levels (77, 78). Vitamin D can influence many different
biological processes and appears to act as an anti-
inflammatory agent on brain tissue (79) as well as to
exert effects on DNA repair processes (80).
Folate
Folate availability has also been suggested as a possible
factor in risk of autism (81). The interest in folate partly
stems from its known role in affecting neurodevelopment
(82, 83). In general, it is thought that folate levels and their
impact on the metabolic pathway for methionine could
play a role in autism risk. Deficiency in this metabolic
pathway has been suggested as a possible causative factor
in autism. Both genetic polymorphisms for the pathway
and folate receptor autoimmunity (84) have been sug-
gested as possible routes to pathway alteration. A recent
review of this topic suggested that the heterogeneity of
the studies conducted to date on folate and autism make
definitive conclusions problematic (85). In particular, the
capacity to examine the potential interactions between
genetic background, folate levels, and gene expression
varied widely among the studies.
Infections and vaccinations
Infections and vaccinations are among the categories of
possible risk factors for autism that have garnered the
most attention. The idea that maternal and/or early
infant infections could influence neurodevelopment and
contribute to adverse outcomes is not restricted to autism
(86). The association of maternal infection and elevated
risk of schizophrenia is well supported by human and
animal research (87) with increased inflammatory cyto-
kine levels in the brain as a likely route to altered
neurodevelopment (88). Among the most well-established
infections associated with a purported increased risk of
autism is congenital rubella infection (89, 90). In a more
limited study, Yamashita et al. (46) reported possible
association between congenital infection with cytomega-
lovirus and occurrence of autism.
Both the stage of the pregnancy and the nature of
the infectious agent appear to be important in the likely
neurological outcome (91). The proposed maternal
infection-autism connection is supported by more general
data as well. Atlado´ttir et al. (92) found evidence that
maternal infection resulting in hospitalization elevated
the risk of autism in the offspring. Some evidence from
animals suggests that maternal inflammation in response
to infectious agents may be an important factor in brain
development (93). In this study, an IL-1 receptor
antagonist was able to protect against the prenatal
neurodevelopmental deficits.
If maternal infections represent a potential risk factor
where there has been recent scientific agreement, the same
cannot be said of vaccinations. Vaccinations, by their
design, are intended to modulate the immune system by
inducing production of a protective and highly specific
immunological response. At issue has been the question of
when and under what circumstances unintended immu-
nomodulation occurs and whether unintended adverse
outcomes associated with vaccinations could affect the
risk of autism. Additionally, among the potential types
of adverse outcomes to vaccinations is the question of
whether concentrations of toxicants (e.g. mercury-
containing thimeresol) and the developmental timing of
exposure are sufficient to produce adverse outcomes such
as autism. It is of note that in many cases when postnatal
childhood exposure to infectious agents elevates risk of
chronic disease, the infectious challenge serves as a
triggering event in children previously made susceptible
(reviewed in Dietert (94)). This is one reason why child-
hood triggers promoting the onset of diseases such as
asthma are often more obvious than are the actual
causative prenatal environmental conditions that estab-
lished susceptibility in the child.
Most of the focus to date involving childhood vaccina-
tion and autism has centered on MMR vaccination.
Specifically, in the case of the risk of autism, several
recent studies indicate that MMR vaccination does not
increase the risk of autism. This includes a study where
the MMR vaccine was administered for a 4-year period
(19891993) in Japan; the incidence of autism was not
different across the interval before, during, and after this
MMR vaccination window (95). Baird et al. (96) reported
no dose response associations between the antibody
response to measles virus or the measles component of
the MMR in children with autism versus two control
groups of children (one control group with specific
educational needs unrelated to autism and a typically
developing group of children). In a very recent case-
controlled study, Mrozek-Budzyn et al. (97) found no
association between either MMR vaccination or single
measles vaccine administration and risk of autism.
Childhood vaccinations play a critical role in redu-
cing the risk of preventable and in some cases life-
threatening illnesses. If one considers the history of
preventing diseases like polio, childhood vaccinations
have been remarkably effective. In a recent review of
environment and autism, Landrigan (4) considered the
evidence for vaccines and autism and concluded that fear
of autism should not result in failure to protect children
against life-threatening illnesses. We concur with this
conclusion.
Environment and autism
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Are there important vaccine safety issues?
The opportunity to prevent serious childhood illnesses
through the use of effective vaccination regimes is a
critical public health measure. In general, vaccine safety
is quite exceptional when compared with overall safety
of pharmaceutical agents and medical procedures as
recently reviewed by House (98). However, the lack of
association with MMR vaccination and risk of autism
does not mean that improved vaccine safety testing is not
important in future strategies to reduce environmental
health risks. There are some issues particularly in the
timing of vaccinations for the developing immune system
(reviewed in Dietert and Dietert (36)) where some
protocols may be more beneficial than others for certain
health risks (99). Additionally, immune dysfunction is a
prominent feature in autistic children and has led to
discussion of possible immunological links with autism
(36, 100, 101).
Stress
Stress can take many forms including infectious, oxida-
tive, physical, and psychological. Each category is worthy
of examination when it comes to risk of autism; some
studies have suggested that stress is a potentially fruitful
area of study when it comes to environmental risk of
autism. Studies differ in scope in that many considered
one or two categories of stress while others examined
more generalized forms of stress, particularly during the
period of pregnancy. Ploeger et al. (45) argued that
disruption of very early developmental events (gesta-
tional days 2040 in humans) may be a route to infantile
autism. Where a stress-based model was employed in
humans, a broad period spanning mid-gestation (prior to
32 weeks of gestation) was of greatest interest (102).
Mueller and Bale (103) reported that a stress experience
early in prenatal development is likely to contribute to
male-oriented patterns of neurodevelopmental disorders.
This is relevant to risk of autism since some neurological
researchers hypothesize that the autistic brain may be a
‘hyper-male’ form (104), and fetal testosterone levels are
thought to be important in the risk of autism (105). Using
a mouse model, Jones et al. (106) suggested that prenatal
stress when combined with genotypic variants in the
mother such as reductions in serotonin transporter, may
result in autism phenotype in the offspring. But not all
studies agree on the association between stress and risk of
autism. For example, Li et al. (107) found no evidence for
an increased risk of autism following the prenatal stress of
maternal bereavement.
Risk identification and reduction: research and
safety testing
Research is an important component in the ultimate
prevention of autism. However, research is most often
after the fact and is reactive to emerging health threats
that have already taken a heavy societal toll. In contrast,
well-conceived safety testing of chemicals and drugs is far
more likely to be proactive in the prevention of develop-
mental conditions affecting the neurological and other
systems. In the case of autism, increased prevalence that
has emerged over the past 3040 years and the targeted
research that has followed to date, have yet to produce a
definite list of causative environmental factors. Still,
safety testing today is not designed to detect the types
of developmental disruptions that are likely to result in
autism (or other recent childhood health threats such as
asthma or type 1 diabetes). Why is the primary response
to this emerging health threat only to be found in
research and not reflected in purposeful and effective
changes to regulations that determine the safety of our
drugs and chemicals? Recently, investigators focused on
the developmental origins of chronic disease called for a
more forceful role of public health officials to reduce the
burden of disease established early in life (108). We
concur with this appeal, which will require a different
level of engagement on issues in developmental toxicity
such as the prevention of autism.
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